By Counterforce Health Team in Koselugo (selumetinib) —

How to Get Koselugo (Selumetinib) Covered by Cigna in Washington: Prior Authorization Guide, Appeal Steps, and State Protections

Answer Box: Getting Koselugo Covered by Cigna in Washington

Quick Path to Approval: Cigna typically requires prior authorization for Koselugo (selumetinib), but Washington state protections help ensure fair coverage decisions. Your fastest route: (1) Have your pediatric oncologist/neurologist submit a comprehensive PA request with NF1 diagnosis, imaging showing symptomatic plexiform neurofibromas, and baseline safety evaluations, (2) If denied, file an internal appeal within 180 days citing medical necessity and FDA approval status, (3) Request external review through Washington's Independent Review Organization if internal appeals fail. Washington law guarantees binding external review for medical necessity denials, and most rare disease appeals succeed when properly documented.

First Step Today: Contact your prescribing specialist to initiate the prior authorization process through Cigna's provider portal or by calling the number on your insurance card.

Table of Contents

Understanding Washington's Insurance Protections

Washington state offers some of the strongest consumer protections in the nation for patients facing insurance denials. Unlike many states, Washington guarantees your right to an independent external review for virtually any medical necessity denial, including rare disease medications like Koselugo.

Key Washington Protections:

  • Binding external review through Independent Review Organizations (IROs) under RCW 48.43.535
  • Step therapy override rights when medically appropriate
  • Expedited appeals for urgent cases (72-hour decisions)
  • Free consumer advocacy through the Office of the Insurance Commissioner
Note: These protections apply to fully-insured commercial plans. If you have an employer self-funded (ERISA) plan, federal rules apply instead, though many employers voluntarily provide similar protections.

Prior Authorization Requirements for Koselugo

Koselugo (selumetinib) is FDA-approved specifically for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. Cigna typically requires prior authorization for this specialty medication.

Coverage at a Glance

Requirement What It Means Documentation Needed
PA Required Yes, through Express Scripts/Accredo Provider submission via portal/fax
Age Limit Pediatric patients ≥2 years Birth certificate or medical records
Diagnosis Confirmed NF1 with plexiform neurofibromas Genetic testing, imaging studies
Symptom Documentation Symptomatic and inoperable tumors Clinical notes, imaging reports
Safety Monitoring Baseline cardiac and eye exams LVEF assessment, ophthalmologic evaluation

Sources: FDA Koselugo labeling, Cigna prior authorization policies

Step-by-Step: Fastest Path to Approval

1. Gather Required Documentation

Who: Patient/family and medical team
Timeline: 1-2 weeks before PA submission
What to collect:

  • Genetic testing confirming NF1 diagnosis
  • Recent MRI showing plexiform neurofibromas
  • Clinical notes documenting symptoms (pain, functional impairment)
  • Baseline LVEF (echocardiogram or MUGA scan)
  • Ophthalmologic examination results

2. Provider Submits Prior Authorization

Who: Prescribing physician (pediatric oncologist/neurologist)
How: Through Cigna provider portal or Express Scripts
Timeline: Cigna has 72 hours for urgent requests, longer for standard reviews
Include: Medical necessity letter addressing FDA-approved indication

3. Monitor Decision Timeline

Standard review: Up to 15 business days
Expedited review: 72 hours (if urgent medical need documented)
Follow up: Call Cigna at the provider services number on your card

4. If Approved: Coordinate Specialty Pharmacy

Koselugo is typically dispensed through specialty pharmacies like Accredo. Your doctor will coordinate shipping and provide dosing instructions based on body surface area.

5. If Denied: Immediate Next Steps

  • Request detailed denial letter with specific reasons
  • Gather additional supporting documentation
  • File internal appeal within 180 days (don't delay)

Common Denial Reasons and How to Fix Them

Denial Reason How to Overturn Key Documentation
"Not medically necessary" Emphasize FDA approval for exact indication FDA approval letter, clinical guidelines
"Experimental/investigational" Cite FDA approval status since 2020 FDA labeling, peer-reviewed efficacy studies
Missing NF1 diagnosis Provide genetic testing results Genetic counselor report, molecular testing
Inadequate symptom documentation Detailed functional assessment Pain scales, quality of life measures, imaging
Safety monitoring incomplete Complete baseline evaluations Cardiology clearance, ophthalmology reports

Source: Common denial patterns from Cigna appeals guidance

Appeals Playbook for Cigna in Washington

Internal Appeals Process

Level 1: Standard Internal Appeal

  • Deadline: 180 days from denial date
  • How to file: Written request to Cigna appeals department
  • Timeline: 30 days for standard, 72 hours for expedited
  • What to include: New clinical evidence, medical necessity letter, relevant guidelines

Level 2: Second Internal Review (if available)

  • Timeline: Additional 30 days
  • Benefit: Fresh review by different medical reviewers

Clinician Corner: Medical Necessity Letter Checklist

When your doctor writes the appeal letter, ensure it addresses:

✓ Confirmed NF1 diagnosis with genetic testing results
✓ Imaging documentation of plexiform neurofibromas
✓ Symptom severity and functional impact
✓ Inoperable status (why surgery isn't feasible)
✓ FDA approval for this exact indication
✓ Safety monitoring plan (cardiac, ophthalmologic)
✓ Treatment goals and expected outcomes

Reference: FDA Koselugo prescribing information

Step Therapy Protections

Washington state law provides strong protections against inappropriate step therapy requirements. Under RCW 48.43.420, you can request a step therapy override if:

  • The required drug is contraindicated
  • The patient has tried and failed the required medication
  • The required drug is expected to be ineffective
  • The patient is stable on current therapy

For Koselugo: Since it's the first FDA-approved treatment for pediatric NF1 plexiform neurofibromas, inappropriate step therapy requirements should be challenged using Washington's medical exception criteria.

Filing a Step Therapy Exception

  1. Use the Washington step therapy exception form
  2. Provide clinical rationale for bypassing step therapy
  3. Submit within required timeframes
  4. Cigna must respond within 3 business days (1 day if urgent)

External Review and State Complaints

If Cigna denies your internal appeals, Washington law guarantees access to binding external review through an Independent Review Organization (IRO).

How External Review Works

Eligibility: Any medical necessity denial after exhausting internal appeals
Deadline: 180 days from final internal denial
Cost: Free to you (insurer pays IRO fees)
Timeline: 15-20 days standard, 72 hours expedited
Decision: Binding on Cigna if favorable

Filing for External Review

  1. Request through Cigna: They must provide instructions and forms
  2. Submit supporting evidence: Medical records, studies, guidelines
  3. IRO assignment: Washington OIC assigns qualified medical reviewers
  4. Decision: Binding determination based on medical evidence

Get Help: Contact the Washington Office of the Insurance Commissioner at 1-800-562-6900 for free consumer advocacy support.

When dealing with complex prior authorization challenges, platforms like Counterforce Health can help by analyzing denial letters, identifying specific appeal strategies, and drafting evidence-backed responses that address payer requirements systematically. Their approach of turning denials into targeted appeals has proven effective for families navigating rare disease coverage battles.

Cost Assistance and Patient Support

Even with insurance approval, Koselugo can be expensive. Explore these assistance options:

Manufacturer Support:

  • AstraZeneca Access 360: Copay assistance and patient access programs
  • Income-based support for eligible patients

Foundation Assistance:

  • Patient Advocate Foundation
  • National Organization for Rare Disorders (NORD)
  • HealthWell Foundation

State Programs:

  • Washington Apple Health (Medicaid) for eligible families
  • Pharmacy assistance programs

Frequently Asked Questions

How long does Cigna prior authorization take in Washington? Standard reviews take up to 15 business days. Expedited reviews for urgent medical needs are completed within 72 hours. Washington law doesn't set specific PA timelines, but federal standards apply.

What if Koselugo is non-formulary on my Cigna plan? You can request a formulary exception through Cigna's standard process. Provide medical necessity documentation and cite the lack of therapeutic alternatives for pediatric NF1 plexiform neurofibromas.

Can I request an expedited appeal if my child's condition is worsening? Yes. Document the urgent medical need and request expedited review. Both internal appeals and external reviews have expedited pathways in Washington for cases involving serious health risks.

Does step therapy apply if we've tried treatments outside Washington? Prior treatment history from other states should count toward step therapy requirements. Provide documentation of previous therapies and outcomes to support your exception request.

What's the difference between Medicare Advantage and commercial Cigna plans for appeals? Medicare Advantage appeals follow federal Medicare rules and use Medicare's Independent Review Entity (IRE), not Washington's state IRO system. Commercial plans follow Washington state appeal protections.

How do I know if my plan is self-funded (ERISA)? Check your Summary Plan Description or ask your HR department. Self-funded plans may not be subject to Washington state protections, though many provide similar appeal rights voluntarily.

What happens if the external review denies coverage? IRO decisions are binding, but you can still file complaints with the Washington OIC if you believe the process was flawed or seek legal counsel for potential court action.

Can Counterforce Health help with Cigna appeals in Washington? Yes, Counterforce Health specializes in turning insurance denials into targeted appeals by analyzing payer policies and crafting evidence-based responses that address specific coverage criteria and state regulations.

From Our Advocates

"We've seen families successfully overturn Koselugo denials by focusing on three key elements: comprehensive documentation of NF1 diagnosis with genetic testing, clear imaging evidence of symptomatic plexiform neurofibromas, and emphasis on FDA approval for this exact pediatric indication. The key is presenting a complete clinical picture that directly aligns with the drug's approved labeling. While outcomes vary, thorough preparation significantly improves appeal success rates."

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies and state regulations may change. Always consult with your healthcare provider and insurance plan for the most current information about coverage and appeals processes.

Sources & Further Reading:

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.